The U.S. government has launched new federal actions to combat drug shortages, including an API stockpile and AI forecasting, but critics say these measures fail to address the root causes: weak incentives for manufacturers and lack of accountability.
Olivia AHOUANGAN | Feb, 10 2026 Read More